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Human synovial sarcoma is caused by a chromosome translocation, which fuses DNA encoding
SSX to that encoding the SS18 protein. Kadoch and Crabtree now show that the resulting cellular
transformation stems from disruption of the normal architecture and function of the human
SWI/SNF (BAF) complex.Damage to our chromosomes is an ines-
capable consequence of cell metabolism
and division. DNA damage can take
many forms, but because their repair is
not always precise, double-strand DNA
(dsDNA) breaks are among the most
dangerous. Indeed, if a dsDNAbreak is re-
paired by nonhomologous end-joiningFigure 1. Generation and Effect of an SS18-SSX Fusion Protein
(Upper) Chromosomal translocation t(X;18)(p11.2;q11.2) fuses the SS18 gene
(on chromosome 18) to SSX1, SSX2, or SSX4 (on the X chromosome), resulting
in a fusion protein in which the eight C-terminal amino acids of SS18 are re-
placed with 78 amino acids from the relevant SSX C terminus. (Lower) The
SS18-SSX fusion protein (green-red) is incorporated into the multisubunit BAF
complex (right), replacing the SS18 protein (green) of normal BAF complexes
(left). This results in eviction and degradation of the BAF47 subunit (right).rather than homologous
recombination, it can poten-
tially result in the fusion of
DNA ends that were not sup-
posed to be joined. Over the
last couple of decades, it
has become clear that chro-
mosome breakage is not
completely stochastic; cer-
tain regions are much more
likely to break than others,
andmoreover, certain specif-
ic chromosome fusion events
are also more likely than
others. In some cases, chro-
mosome translocations even
fuse protein-coding genes in
frame so that a specific, novel
protein species arises. The
existence of recurring fusion
events has become clear
from the study of human can-
cers, including several types
of leukemia, and the exam-
ples of oncogenic transfor-
mations correlating with the
generation of fusion proteins
are unexpectedly plentiful (re-
viewed by Saha and Jones,
2005; Taki and Taniwaki,
2006). Interestingly, in the
last couple of decades
research has shown that thetransforming fusions are often between
a protein with a general function in tran-
scription or in chromatin modification
and a ‘‘targeting domain’’ in another
protein (a DNA-binding domain, for
example). It is easy to imagine how such
protein fusions might lead to cellular
deregulation: genes in the vicinity of theCell 1recognition sites for the DNA targeting
domain couldbe inappropriately activated
(or, alternatively, repressed), resulting in
cellular transformation. A much studied
example is the fusion of the DNA-binding
domain ofMLL to subunits of the so-called
super elongation complex (Smith et al.,
2011). As with mixed-linage and acute53, March 2myeloid leukemias (MLL and
AML, respectively), human sy-
novial sarcomas are caused
by translocations generating
new fusion proteins. The
translocation event observed
in this type of cancer fuses
the SS18 gene on chromo-
some 18 and one of three
SSX genes (SSX1, SSX2, and
SSX4) found in a cluster on
chromosome X, which gener-
ates a stable SS18-SSX fusion
protein (Figure 1, upper).
Although earlier data sug-
gested that SS18 interacts
with chromatin-remodeling
complexes (Thaete et al.,
1999; Nagai et al., 2001), the
molecular consequence of
fusion protein expression
have been unclear.
In a detailed and compelling
study published in this
issue of Cell, the mechanism
of cellular transformation in
human synovial sarcoma is
now unveiled. Kadoch and
Crabtree (2013) initially pro-
vide evidence that SS18 is
a hitherto overlooked, integral
subunitof thehumanSWI/SNF
(BAF) chromatin-remodeling8, 2013 ª2013 Elsevier Inc. 11
complex. It is tightly associated with the
catalytic Brg subunit, dissociating from
themultisubunit complex at amuch higher
urea concentration than the well-known
BAF47/hSNF5/INI1 or BAF250/ARID1
subunits, for example. Importantly, the
SS18-SSX fusion protein becomes
incorporated into the BAF complex in
place of SS18, and this in turn results in
the eviction, and subsequently proteaso-
mal degradation, of the BAF47 subunit
(Figure 1, lower).
BAF47 is already a well-established
tumor suppressor. For example, loss of
the BAF47 gene causes extremely
aggressive malignant rhabdoid tumors
(MRTs), and its re-expression in MRT
cells stops their proliferation (Kia et al.,
2008). It might therefore be expected
that eviction of BAF47 also plays an
important role in human synovial sar-
coma tumorigenesis. In agreement with
this idea, the altered BAF complex
binds the Sox2 locus and reverses
polycomb-mediated repression, result-
ing in activation of this pluripotency
gene. Sox2 is uniformly expressed in
human synovial sarcoma tumors and is12 Cell 153, March 28, 2013 ª2013 Elsevier Iessential for their proliferation, so its
anomalous activation may well be
transformative.
It is intriguing that evictionofBAF47,and
thus transformation, depends on only two
amino acids of the SSX protein, explaining
whySSX1,SSX2, andSSX4, but notSSX3,
are observed in synovial sarcoma fusion
proteins: SSX3 has methionine-isoleucine
in place of the evicting lysine-arginine
amino acid pair found in the otherwise
highly conserved SSX homologs. Alto-
gether, this fascinating story of a unique
oncogenic transformation mechanism un-
derscores the frustratingly random nature
of human cancer: if it invariably elicits effi-
cient programs to drive cellular transfor-
mation, even an exceedingly rare and un-
likely event like that in human synovial
sarcoma may become a recurring human
health issue.
Encouragingly, the findings of Kadoch
and Crabtree indicate potential avenues
of therapeutic intervention. As the authors
point out, if—for example—a decoy
molecule could be developed that
causes the BAF47-evicting amino acids
of the transformative SSX molecules tonc.resemble the corresponding surface of
the benign SSX3 protein it would offer
some hope for the development of a
new treatment that builds on understand-
ing the fusion protein’s unusual mecha-
nism of action.REFERENCES
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Chen et al. demonstrate a newway bywhich noncoding RNAs tailor the function ofmulticomponent
complexes. They show that a noncoding RNA interacts with an exoribonuclease, altering its sub-
strate specificity and enzymatic activity by serving as a ribonucleoprotein scaffold and, perhaps,
a gate for entry of the RNA substrate.Multiprotein complexes are the work-
horses of the cell and provide critical
functions that are necessary for cellular
growth and viability by merging related
activities into compact molecular ma-
chines. Protein-protein interactions are
well known to be involved in allostericregulation, altering substrate specificity
and localization of enzymatic function
to specific subcellular compartments.
Several RNAs that serve as scaffolds
for such molecular machines have
been described, including yeast TLC1
RNA and telomerase (Lebo and Zappulla,2012), pRNA and the Ø29 DNA-
packaging motor (Harjes et al., 2012),
and IRES elements and translation fac-
tors. The ability of RNAs to scaffold mo-
lecular machines is also being inves-
tigated for synthetic biology applications
(Delebecque et al., 2012). Given the
